Results 281 to 290 of about 146,174 (378)

Vipera berus Bites in Germany From 2012 to 2023: A Retrospective Analysis of Poison Center Databases. [PDF]

Dtsch Arztebl Int
Rae J, Rahden P, Hosemann D, Lüddecke T, Blessmann J, Matzke S, Kappel S, Prasa D, Wagner R, Stich R, Steindl D, Stedtler U, Kreuels B.   +12 more
europepmc   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Molecular effects of clinically relevant chemotherapeutic agents on choline phospholipid metabolism in triple negative breast cancer cells. [PDF]

Transl Oncol
Tressler CM, Sonkar K, Cheng M, Ayyappan V, Cai R, Glunde K.   +5 more
europepmc   +1 more source

Recent Progress on Phospholipases: Different Sources, Assay Methods, Industrial Potential and Pathogenicity

Applied Biochemistry and Biotechnology, 2011
L. Ramrakhiani, S. Chand
semanticscholar   +1 more source

Phospholipase C and phosphatidylinositol phospholipase C.

Clinical Chemistry, 1987
K, Hawrylak, R A, Stinson
openaire   +2 more sources

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Assessing the Utility of Broad-Acting Inhibitors as Therapeutics in Diverse Venoms. [PDF]

Toxins (Basel)
Kadler R, Morrison B, Yanagihara AA.
europepmc   +1 more source

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

Mechanisms and research progress of insect-derived medicines in intervention for ischemic stroke. [PDF]

IBRO Neurosci Rep
Xu C, Guan Y.
europepmc   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source